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Background: The reported incidence of Postoperative Residual Curarization (PORC) is still 
unacceptably high. Clinically counterintuitively, the capacity of intraoperative Neuromuscular 
Monitoring (NMM) to significantly reduce the incidence of PORC has yet to be established 
from pooled clinical studies. The present meta-analysis aimed to gather data from 1979 to 
2019 to reanalyse this relationship. 
Methods: English language, peer-reviewed and operation room adult anaesthesia setting 
articles published between 1979 and 2019 were searched for on PubMed, Cochrane Central 
Register of Controlled Trials, ISI-WoK and Scopus. The primary outcome was PORC 
incidence as defined by a at/post-extubation Train of Four ratio (TOFR) lower than 0.7, 0.9, 
or 1.0. Additional collected variables included the duration of action category of used 
NMBAs, sugammadex or neostigmine use and the technique of anaesthesia maintenance.  
Results: Fifty-three studies (109 study arms, 12664 patients) were included. The pooled 
PORC incidence associated with the use of intermediate duration NMBAs and quantitative 
NMM was 0.115 (95%CI: 0.057 - 0.188). This was significantly lower than the PORC rate for 
both qualitative NMM (0.306; 95%CI: 0.09 - 0.411) and no NMM (0.331; 95%CI: 0.234 - 
0.435). Anaesthesia type did not significantly affect PORC incidence. Sugammadex use was 
associated with lower PORC rates. The GRADE global level of evidence was very low and 
the refined assessment of the network meta-analysis by means of a CINeMA analysis raised 
concerns on within- and across-study bias. 
Conclusions: Quantitative NMM significantly outperforms both subjective and no NMM 
monitoring in reducing PORC as defined by a TOFR < 0.9. 
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residual curarization; train of four; train of four ratio; 
Introduction 
 
Neuromuscular Blocking Agents (NMBAs) are part of the daily anaesthetic practice world-
wide. 
In the United states alone, 51.4 million surgical procedures per annum are estimated to take 
place.1 In Europe, estimations approximate 34.8 million procedures.2 Combined worldwide 
estimates put forward a global volume of 234.4 million surgical procedures per year.2 The 
proportion of these in which NMBAs are used is not accurately known and only speculated 
on.1 
Despite international recognition of quantitative neuromuscular monitoring (NMM) as an 
absolute and core necessity in modern anaesthesia care, the incidence of Postoperative 
Residual Curarization (PORC) due to ineffective or absent NMM remains unacceptably high 
(up to 60%) – especially considering its preventable nature.1,3 
The substandard NMM adoption is attributed to both logistical/material factors (limited 
availability, suboptimal practicality/ergonomics, time-pressure), as well as to operator-related 
phenomena (undereducation, overconfidence).3,5–7 
Although clinical intuition and expert opinion put NMM forward as essential for PORC 
prevention, indexed literature reports heterogeneous findings and this subject has only been 
addressed once by means of a meta-analysis.8 Pooling studies from 1979 to 2005, Naguib 
and co-workers have counter-intuitively failed to statistically demonstrate that intraoperative 
NMM leads to PORC prevention.8,9 
The present meta-analysis aims to reanalyse evidence for the effect of different subtypes of 
intraoperative NMM on PORC. Building on the original meta-analysis, published data up to 






Prior to commencement, the protocolized meta-analysis was registered on the PROSPERO 
Database (ID 137975, registration number CRD42020137975). 
The literature search strategy involved the following databases: PubMed, Cochrane Central 
Register of Controlled Trials, ISI Web of Knowledge and Scopus. The keywords used were: 
Curarization, Post-operative, Neuromuscular blockers, Muscle relaxants, Residual block, 
Residual curarization. Inclusion criteria were: publication between January 2006 and May 
2019; English language; peer-reviewed; human adult studies; operating room anaesthesia 
setting. Exclusion criteria were: abstracts; editorials; paediatric, cardiac surgery and 
neuromuscular disorder patients; duplicate populations. 
The reported outcome was the incidence of PORC as defined by a at- or post-extubation 
Train of Four (TOF) ratio lower than 0.7, 0.9, or 1.0. The cut-off of 0.7 has been included for 
historical reasons. As reported by Naguib and colleagues, earlier studies used this value for 
PORC definition.8 Conversely, more recent studies have reported on a threshold of 1.0.10–14 
Thus, this value was also included. 
Data was screened by HC, MV and LG, with full text review of potential eligible studies. 
Disagreements were disputed recurring to a third co-author (WC, PF, JP). A standardised 
pre-piloted Excel form was used to extract data from the included studies. Extracted 
information included: study name, authorship and publication date; participant number 
subdivided per study arms; study setting; study population and recruitment dates; 
intervention (intraoperative NMM type, stimulating current in milliamperes) and control 
conditions; NMBA used and dose; NMBA duration category (short, intermediate, or long); 
type of anaesthesia (total intravenous anaesthesia - TIVA, volatile anaesthesia - VA - or 
combined); duration of anaesthesia; used of neostigmine or sugammadex; outcome (PORC 
defined by a TOF ratio <0.7/<0.9/<1.0) and timing of measurement; oxford quality scoring 
system and Cochrane Collaboration’s risk of bias.15 Short duration of action NMBAs included 
the drug succinylcholine. Intermediate duration NMBAs included atracurium, cisatracurium, 
mivacurium, vecuronium and rocuronium. Long duration of action NMBAs included 
gallamine, pancuronium and d-tubocurarine. Missing data was requested from study authors 
by means of e-mail contact. 
The level of certainty was assessed using the Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) working group guidance.16,17 
To the constructed database involving articles from 2006 onwards, those of the meta-
analysis of Naguib and colleagues (1979 - 2006) were added.8 These were similarly re-
analysed. 
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow 
diagram representing the data processing is presented in figure 1. The pooled studies and 
main collected variables are displayed on table 1. 
 
Statistical Analysis 
The primary analysis’ goal was to examine whether PORC (defined by post-extubation TOF 
ratio values above the cut-off of either 0.7, 0.9 or 1.0) was more or less likely depending on 
the type of NMM used intraoperatively: no monitoring, qualitative monitoring (Peripheral 
Nerve Stimulation - PNS), or quantitative monitoring (TOF-ratio quantification). In as far as 
possible, the evaluation also accounted for the duration category of NMBAs used 
intraoperatively (short, intermediate or long duration of action), use of antagonizing drugs 
(sugammadex or neostigmine), type of anaesthesia maintenance technique (VA, TIVA or 
both) and year of publication. A three level mixed effect model was used to analyse one or 
more proportions per study obtained in different conditions..18 The proportions in each of the 
relevant conditions were transformed in order to normalize them using the Freeman Tukey 
arcsine transformation which resulted in effect size estimates (proportion) and variance. 
Secondly, these transformed effect sizes were pooled using a linear mixed model conditional 
on these variances. The lowest of the three levels consists of the Freeman Tukey 
transformed proportions with appropriately transformed variances. A second level defines 
the conditions under which these proportions were obtained, including information for 
example on the type of intraoperative NMM/NMBA. The third level is necessary to identify 
the study so that within study correlations between proportions can be incorporated. To 
accommodate the embedding of sometimes more than one proportion within a study, an 
extra level was used to incorporate within study correlations. Afterwards, the resulting 
estimates were back-transformed to the proportion scale.  
The analysis was repeated twice, once for the proportions related to the TOF-ratio cut-off of 
0.9 and once for the proportions related to the 0.7 cut-off. Pairwise contrasts were used to 
compare the 3 types of monitoring with Shaffer adjusted p-values. A forest plot was used to 
illustrate the back-transformed proportions for the various studies and their pooled 
proportions. 
An intercorrelation analysis preceded the above-mentioned calculations in order to put 
forward a statistical model without confounding multicollinearity issues. In fact, due to high 
intercorrelation concerns between some of the collected variables, a model encompassing 
all relevant information could not be created. For this purpose, a model accounting for the 
monitoring type, NMBA duration category and type of anaesthesia maintenance (main 
model) was used as the central model to answer the main questions within the present 
meta-analysis. A secondary analysis addressed the effect of variables such as 
pharmacological antagonism in combination with monitoring type and anaesthesia 
maintenance but without NMBA duration category. Another secondary analysis addressed 
the trend over time with publication year in combination with NMM type only. No sensitivity 
analysis was planned. 
Data was classified as missing only if not reported in the original article and eventual 
accompanying supplements, and only after attempts to contact the corresponding authors 
were unsuccessful. Further statistical processing was carried out by removing the missing 
data from the analysis for which missingness at random was assumed. 
Selective outcome reporting and publication biases were assessed using an evaluation of 
the asymmetry in funnel plots according to Cochrane guidelines.15,16 
The meta-analysis was performed with the R package metafor (R version 3.6.2, 12 
December 2019; Metafor package 2.1-0).19 
A Confidence In Network Meta-analysis (CINeMA) was used for purposes of confidence 
analysis in the Network meta-analysis (NMA).17,20  
A 6-node treatment network was graphically summarized and used as base for the later bias 
relationship presentation within the network (supplementary material). The herein included 
elements were the duration category of the NMBA (short, intermediate, long) and NMM 
category (no, qualitative and quantitative). The included nodes and their relationships derive 
from their practical combination in the clinical setting. No alternative network geometries 
were explored. 
The in the CINeMA analysis incorporated quality domains were: within-study bias; across-
studies bias; indirectness; imprecision: heterogeneity; and incoherence. This analysis 
referred to the findings relating to the PORC TOF-ratio cut-off of 0.9. Data was listed in “arm 
per arm” fashion, with unreported data within a specific study leading to its exclusion from 
the global CINeMA analysis. Outcome was binarily analysed (presence vs absence of 
PORC) based on a Random Effects analysis model with Risk Ratio as the effect measure. 

















The proportions obtained in 53 studies were pooled with a 3-level mixed model conditional 
on observed variances. Twenty-four of these studies refer to the time period between 1979 
and 2006 and were upcycled and re-analysed from the original meta-analysis of Naguib and 
colleagues.8 Further indexed database searches referring to the period from 2006 up to May 
2019 ultimately yielded 29 additional studies. In total, 12664 patients were included in the 
analysis, distributed through a total of 109 study arms. There were no additional studies 
awaiting classification. 
Short-acting NMBAs were used in only one of the studies and were thus excluded from the 
analysis.21 Long-acting NMBAs were given to a total of 665 patients, having the remaining 
majority received intermediate-acting NMBAs (n = 11556). In one study with four intervention 
arms and a total of 255 patients, the duration category of the NMBA could not be identified.22 
Neostigmine was used in 6272 patients, and sugammadex on 663 patients. The remaining 
patients had either unreported antagonist use or an unclear reversal drug allocation that 
precluded an unbiased analysis. Only one study included the use of Pyridostigmine.58 
A potent inhalational agent was used as the single anaesthesia maintenance technique in 
4631 patients. TIVA was used in 1622 patients. Combined use of volatile anaesthesia and 
TIVA was used in 111 patients. The remaining cases had either unreported or unclear 
anaesthesia maintenance technique allocation. 
In 4416 patients, no intraoperative neuromuscular monitoring was used. Qualitative 
monitoring was used on 1528 patients, and 6181 were monitored by means of a quantitative 
device. 
The initial intercorrelation analysis showed that when only considering the monitoring type 
and NMBA duration category there was no multicollinearity impeding their combination into 
an additive model. The top-up with additional predictors (anaesthesia type and 
pharmacological antagonism) raised a clear multicollinearity issue, as the drug duration 
category was strongly correlated to pharmacological antagonism and publication year. 
Pharmacological antagonism was on itself strongly related to the publication year. Although 
publication year related in proximity to data collection year, this might not always be the case 
and heterogeneity exists for this purpose. 
The relation of both the type of NMBA and of pharmacological antagonism with the 
publication year complicates drawing conclusions on whether changes in PORC proportions 
relate to changes in procedure or other changes over time. The correlation coefficients 
obtained when focusing solely on the intermediate duration NMBA, the most prevalent 
NMBA category, are as follows: NMM type vs publication year: - 0.005; NMM type vs 
Anaesthesia maintenance type: 0.047; NMM type vs antagonist use: 0.233; Anaesthesia 
maintenance type vs publication year: -0.293; antagonism use vs publication year: 0.287; 
anaesthesia maintenance type vs antagonist use: -0.287. 
Not all combinations of intraoperative neuromuscular monitoring and neuromuscular 
blocking agent were frequent within the constructed data set. Additionally, as stated above, 
some studied variables were not reported in some of the included studies. At least 
marginally all three possible combinations of pharmacological antagonism (none, 
neostigmine, sugammadex) and all three types of anaesthesia maintenance options (potent 
inhalational agent, TIVA, or both) were observed at least 7 times. 
Only the intermediate and long-duration NMBA category in combination with the different 
intraoperative neuromuscular monitoring modalities (none, qualitative or quantitative) were 
kept for further analysis.  
Considering the above mentioned factors, the statistical analysis was subdivided into 3 
different models: 
 
1 - Main model: a model that included the variables NMM type, NMBA category and 
Anaesthesia maintenance type. 
2 - Antagonist model: encompassed the NMM category, Anaesthesia maintenance type and 
Pharmacological Antagonism as variables. 
3 - Trend model: a model combining the NMM type and publication year in order to make an 
evolution analysis of monitoring use. 
 
The main model retained a total of 51 study arms, part of 39 studies. The antagonist model, 
by excluding the NMBA duration category, held 76 study arms for analysis. Finally, the trend 
model trimmed the observations down to 69. 
In all statistical models, analysis of the primary outcome was subdivided according to the 
TOF-ratio cut-off used for its definition: 0.7, 0.9 and 1. It appeared that data on the PORC 
with 1.0 TOF-ratio cut-off was not often available, resulting in only 5 observed proportions. It 
was therefore excluded from the analysis. Data on PORC associated with the use of 
Pyridostigmine resulted in only 2 observed proportions and was similarly excluded from the 
analysis. 
 
1 - Main model 
1.1 - TOF-ratio cut-off 0.7 
For the cut-off at 0.7, the analysis suggests that there is no sufficient evidence to conclude 
on any effect of the type of Anaesthesia maintenance to exist. Significant differences 
between monitoring methods could not be statistically objectivated, and 95% confidence 
intervals (95%CI) for the different NMM and NMBA combinations overlapped. 
Both the test for residual heterogeneity (QE(32df) = 378.47, p = 7.76×10−54) and for 
moderators (QM(6df) = 148.27, p = 1.9×10−29) were strongly significant. 
The variances at the study level and the within study level (different types of effect) are 
0.0125 (27), 0.0217 (38) with the number of unique instances in between parentheses. The 
corresponding forest plot includes the observed proportions and is available as 
supplementary material. 
 
1.2 - TOF-ratio cut-off 0.9 
The analysis suggests that quantitative monitoring results in lower PORC than both no 
(Coefficient of 0.208; 95%CI [0.048;0.368]; p = 0.005) and qualitative NMM (Coefficient of -
0.269; 95%CI [-0.423;-0.114]; p < 0.001). No differences between the NMBA duration 
category were suggested (Coefficient of -0.340; 95%CI [-0.761;0.082]; p = 0.157). 
Qualitative NMM wasn’t significantly different from no NMM (Coefficient of -0.061; 95%CI [-
0.269;0.147]; p = 0.866). Similarly to the 0.7 cut-off, there is no suggestion the anaesthesia 
type influences cumulative PORC proportions. 
The test for residual heterogeneity (QE(29df) = 803.20, p = 2.46×10−150) and for moderators 
(QM(6df) = 139.49, p = 1.28×10−27) were strongly significant. The variances at and within 
study level were, respectively, 0.0689 (30) and 0.0025 (35) with the number of unique 
instances in between parentheses. 
The forest plot is presented as supplementary material. Due to the paucity of observations 
for the combinations of qualitative monitoring and both TIVA and the combination of TIVA 
and a potent inhalational agent, no back transformed pooled proportions could be computed. 
Considering the absence of an effect of anaesthesia type, a model pooling the PORC rates 
independently of anaesthesia type was used in order to clearly summarize this meta-
analysis findings (table 3). Within this model, quantitative monitoring resulted in lower PORC 
proportions than both none (Coefficient: 0.260; 95%CI [0.144;0.376]; p < 0.001) or 
qualitative intraoperative neuromuscular monitoring (Coefficient: 0.234; 95%CI [0.119;0.348]; 
p < 0.001). Qualitative monitoring didn’t significantly differ from no monitoring (Coefficient of 
0.026; 95%CI [-0.082;0.135]; p = 0.919). The strong significance of residual heterogeneity 
(QE(45df) = 1178.63, p = 1.83×10−217) and moderator tests (QM(4df) = 230.31, p = 
1.13×10−48) was maintained. A model-concordant forest plot is presented in figure 2. 
 
2 - Antagonist model 
2.1 - TOF-ratio cut-off 0.7 
This sub-analysis suggests only a difference between quantitative and no NMM (Coefficient 
of 0.264; 95%CI [0.051;0.477]; p = 0.009). Neither pharmacological antagonism nor 
anaesthesia maintenance type seem to influence PORC. Residual heterogeneity testing 
(QE(32df) = 334.94, p = 3.56×10−52) and moderator testing (QM(7df) = 147.30, p = 
1.50×10−28) showed strong significance. The variances at and within study level are 0.0073 
(27) and 0.0298 (39), respectively, with the number of unique instances in between 
parentheses. 
 
2.2 - TOF-ratio cut-off 0.9 
Quantitative monitoring yielded lower PORC proportions than qualitative (Coefficient of -
0.259; 95%CI [-0.413;-0.106]; p < 0.001) and no NMM (Coefficient of 0.214; 95%CI 
[0.055;0.372]; p = 0.004). Qualitative monitoring didn’t differ significantly from no monitoring 
(Coefficient of -0.047; 95%CI [-0.253;0.159]; p = 0.932). Sugammadex was associated with 
lower PORC than Neostigmine (Coefficient of 0.196; 95%CI [0.060;0.332]; p = 0.002). The 
forest plot for the pooled PORC proportions is given as supplementary material.  
Both the test for residual heterogeneity (QE(33df) = 678.84, p = 1.33×10−121) and for 
moderators (QM(7df) = 145.49, p = 3.60×10−28) are again strongly significant. The variances 
at the study level and the within study level (different types of effect) are 0.0714 (30) and 
0.0023 (40), respectively, with the number of unique instances in between parentheses. 
 
3 - Trend model 
3.1 - TOF-ratio cut-off 0.7 
The analysis suggests that there is only a difference between quantitative and no NMM 
(Coefficient of 0.221; 95%CI [0.012;0.430]; p = 0.035). There is a consistent reduction of 
PORC incidence with time, although with the variance coefficients’ confidence intervals 
assuming both positive and negative values (Coefficient of -0.006; 95%CI [-0.014;0.003]; p = 
0.295). The isolated proportions plot is available as supplementary material. 
Both the test for residual heterogeneity (QE(42df) = 450.10, p = 9.17×10−70) and for 
moderators (QM(4df) = 225.06, p = 1.53×10−47) were strongly significant. The variances at 
and within study level are, respectively, 0.0075 (32) and 0.0273 (46), with the number of 
unique instances in between parentheses. 
 
3.2 - TOF-ratio cut-off 0.9 
The analysis confirms the earlier difference between quantitative and qualitative (Coefficient 
of -0.236; 95%CI [-0.343;-0.129]; p < 0.001), as well as of no NMM (Coefficient of 0.246; 
95%CI [0.136;0.355]; p < 0.001), with the latter yielding higher PORC proportions. PORC 
significantly decreased over time (p = 0.001). Isolated plotting of proportions is represented 
in figure 3. 
Again, residual heterogeneity (QE(48df) = 1649.48, p = 3.13×10−314) and moderators 
(QM(4df) = 264.66, p=4.52×10−56) tests were strongly significant. The variances at and within 
study level are, respectively, 0.0620 (41) and 0.0009 (52), with the number of unique 
instances in between parentheses. 
 
Confidence In Network Meta-analysis (CINeMA) 
A network plotting of bias relationship within the present meta-analysis was made selectively 
for the PORC TOF-ratio cut-off of 0.9 within the Main model. This selectivity pertained to the 
international recognition of this cut-off as the most clinically relevant for PORC definition3. 
The CINeMA analysis was based on a total of 82 study arms (17 excluded due to missing 
data). Risk of Bias and Indirectness were summarized as averages, risk ratio (RR) used as 
size of effect measure with a conservative cut-off of 0.1. 
The network plot (supplementary material) illustrates the bias relationship for the different 
comparisons. The average risk of bias contribution per binary comparison is also available 
as supplementary material. 
Direct evidence for the majority of the comparisons of interest was available, being absent 
for the comparisons of long duration NMBAs and quantitative NMM, as well as for short 
duration NMBAs and no/qualitative NMM. In fact, direct comparative evidence was present 
for the comparisons between Intermediate-duration NMBAs (A) and all the different 
monitoring modalities (D - No Monitoring; E - Qualitative monitoring; F- Quantitative 
monitoring). 
There were moderate within-study bias concerns for the conclusions drawn for the 
abovementioned comparisons. All are suspect for across-study bias. 
In terms of Indirectness rating, all of the abovementioned comparisons rated low on bias risk 
(illustrations available as supplementary material). 
Imprecision analysis raised no concerns for the selected RR cut-off of 0.1, meaning there 
was agreement in relation to a clinically important effect. Quantitatively speaking, this is 
translated by the following estimates and ranges: Intermediate NMBA and No monitoring: 
RR 1 [0.941;1.062], I2 = 0%, τ2 = 0; Intermediate NMBA and Qualitative Monitoring: RR 1 
[0.930;1.075], I2 = 0%, τ2 = 0; Intermediate NMBA and Quantitative Monitoring: RR 1 
[0.927,1.079], I2 = 0%, τ2 = 0. 
In terms of heterogeneity, no concerns were raised. The estimated value of between-study 
variance for the network meta-analysis was 0, with confidence and prediction intervals 
agreeing in relation to the clinically important effect. There were similarly no concerns raised 
for incoherence within the network. A random-effects design-by-treatment interaction model 
for global testing yielded for this purpose a χ2 statistic of 0 based on 2 degrees of freedom 
analysis (p = 1). The CINeMA summary of results is presented in table 2. 
 
Publication bias was assessed by graphing residual values against the corresponding 
standard error in a funnel plot. The process was repeated for every statistical analysis model 
and for every analysed TOF-ratio cut-off. There was no serious indication of any systematic 
heterogeneity bias (figure 4). One study clearly shows a proportion that is different from what 
would be expected based on the available information in the model.23 
The summary of findings for the clinically relevant TOF-Ratio cut-off of 0.9 is presented with 
Standard Cochrane format in table 3.16 Bias grading has been specifically assessed by 
means of the CINeMA analysis as discussed above. Each individual studies’ per domain 



























In contrast with the work of Naguib and colleagues, the present meta-analysis suggests that 
intraoperative neuromuscular monitoring does significantly reduce PORC.8 When 
considering a TOF-ratio cut-off of 0.7, no significant difference can be found between NMM 
subtypes, in spite of a tendency for objective monitoring to yield lower PORC proportions. 
Nonetheless, data analysis in the light of a more consensually accepted TOFR cut-off (0.9), 
reveals that objective monitoring significantly outperforms both subjective and absent 
monitoring.1,3 The growing awareness for PORC and consistent reporting of high PORC 
rates with its associated negative clinical impact might partially explain this shift.5,7,24–26 
Publishing of consensus groups’ updates on monitoring standards have also given this 
phenomenon a momentum.3,25 This has additionally been paralleled with the marketing of 
new quantitative neuromuscular monitors and equivalent practical solutions.27–29 
The observation in the original meta-analysis that long duration NMBAs are associated with 
a higher PORC incidence than its intermediate counterparts was not held statistically within 
the present study, although a same sided trend was present.8 This must be interpreted in 
light of the relative absence of recent studies involving long-duration NMBAs. In fact, from 
the year 2006 onwards no additional articles involving long-acting NMBAs have been found. 
The most recent of these dates back to 2000 and were already included in the original meta-
analysis.8,30 Considering that long-duration NMBAs are rarely used in modern western 
anaesthesia practice, this fact probably carries more historical than clinical relevance. 
Concerning intermediate duration NMBAs (used on 91% of the pooled patient population), 
no subanalysis could be performed to study the effect of NMBA dosing on PORC. In fact, 
although the majority of studies did register cumulative administered doses, an 
anthropometric- and time-adjusted dose reporting (expressed as ED95 equivalent dose kg-1 
h-1) was scarce. This precluded what would be a representative analysis of the dosing effect. 
The studies included in this meta-analysis are not fully homogeneous from a methodological 
point of view. In fact, the first heterogeneity aspect lies on the definition of the primary 
outcome itself. Although PORC is consistently defined throughout the included studies by 
means of a fixed TOF-ratio (0.7, 0.9 or 1.0), the time-point and method of measurement 
varied considerably. In fact, timing ranged from an immediate post-extubation moment 
21,22,31–38, to measurement post-PACU arrival or at a fixed time-point.10–14,39–53 Some studies 
didn’t specify the measurement time point at the PACU at all.54 Globally considered, 84 of 
the 109 included study arms (77%) reported PORC based on TOF-ratios measured at the 
PACU.10–14,30,35,40–46,48–54,54–71 
Additional intra-study heterogeneity is introduced by the fact that measurements post PACU 
arrival were not consistently standardized. Moreover, there was no reporting on transport 
times between the operating room and the PACU, nor mentioning of a possible correction 
factor.  
Monitoring techniques similarly presented inter-study heterogeneity. Although most study 
arms (88%) reported using either accelero- or kinemyographic techniques, electro- or 
mechanomyographic methods were used in smaller proportions (8 and 5 of the 109 study 
arms, respectively). It has been shown that accelero- and kinemyography can significantly 
diverge not only between themselves, but also from electromyography and 
mechanomyography.72–78 It is similarly unclear if movement artifact prophylactic measures 
were adopted whenever accelero- or kinemyography was used, as well as if supra-maximal 
current was used for electrical ulnar nerve stimulation. In fact, only 14 studies have explicitly 
protocolised usage of supra-maximal currents.23,30–33,35,36,38,47–49,58,63,79 Moreover, the reliance 
of accelero- or kinemyographic techniques on movement for their measurements, associated 
with the fact that most of the PORC measurements took place on awake patients (thus 
possibly moving) and with the fact that these techniques have been used in the great 
majority of the included studies (35 out of 53, or 66%) to confirm the presence or absence of 
PORC, has to be seen as an important limitation on the global accuracy of the pooled 
primary outcome. 
The presence of a strong relation between some of the collected variables impeded the 
construction of a larger PORC analysis model. Consequently, more restricted models were 
used to answer specific questions. Specifically, when considering the influence of the 
anaesthesia maintenance technique, the variable could be analysed in the light of the NMBA 
and type of monitoring use, but not co-corrected for pharmacological antagonism or 
publication year. The generalised absence of reporting on time- and anthropometric- 
corrected dosing of NMBAs further restricted a holistic analysis. In the light of these 
restrictions, although it is physiologically recognised that potent inhalational agents prolong 
neuromuscular block, their use does not seem to play a significant role according to our 
results.80–83 The same conclusion applies to TIVA. These results align with those of Naguib 
and colleagues.8 
Similarly to the anaesthesia maintenance technique, the effect of pharmacological 
antagonism is similarly based on more restricted statistical models. The analysis is further 
complicated by significant inter- and intra-study heterogeneity issues concerning the time of 
antagonist administration. For the cut-off of 0.9, the analysis suggests lower PORC 
incidences with sugammadex. Besides the pharmacological principles underlying its 
established efficacy and efficiency, the fact that sugammadex is less subject to the variable 
efficacy effects due heterogeneity in administration timing might explain the obtained results. 
Again, no accounting for dosing took place in significance testing for this purpose. 
The pharmacological selectivity of sugammadex, the heterogeneity of the NMBAs used in 
the included studies, the non-holistic nature of the statistical models used, and the relative 
smaller number of patients receiving in sugammadex in comparison to neostigmine (663 vs. 
6272, respectively) should be assumed as possible confounders when drawing conclusions 
related to sugammadex use. Notwithstanding the undisputable usefulness of a 
pharmacological milestone such as sugammadex, it is important to reiterate that although it 
reduces PORC, it does not eliminate it. Reported heuristics and overconfidence concerns 
with respect to NMM in general pre-emptively suggest a potential false sense of security that 
might be associated with sugammadex use.5–7 As shown within the present analysis, 
sugammadex does not eliminate PORC and its use and monitoring should be guided by 
appropriate quantitative NMM. The use of infra-therapeutic dosing schemes (“vial-saving” 
dosing strategies) reinforces this need.84,85 
The present analysis didn’t control for variables that are similarly known to potentiate 
neuromuscular block (temperature, antibiotics, ionic imbalances, among others). Present 
inferences are thus dependent on active control of these factors within the included studies, 
which is sub-optimally reported. 
When considering the yearly evolution of PORC, one observes a progressive reduction 
independent of the monitoring modality and cut-off. The differences are clearer when 
reporting on a TOF-ratio of 0.9. Curiously one observes a similar reduction of the PORC 
rates for the less accurate neuromuscular monitoring modalities (none or qualitative). 
Moreover, these are reduced through time to a proportionally greater extent than those with 
quantitative monitoring. In the light of the absence of flagrant publication bias signs, such 
positive evolution might translate the increased awareness and sensibilisation efforts within 
the anaesthesia community.3,5–7,56 Unfortunately, a possible underlying effect of the almost 
effective extinction of long-duration NMBAs couldn’t be analysed due to collinearity issues. 
Within the year dependent PORC variation analysis one should acknowledge the potential 
intra-category bias due to the inherent limitations of each of the different quantitative 
monitoring modalities used for the quantification of PORC. In fact, the accurate but now 
virtually extinct mechanomyography has been progressively replaced by kine- or 
acceleromyographic technologies. Within the included studies, its last reported use dates 
back to 2002.36 The more practical and user-friendly nature of acceleromyography comes at 
a known practicality/accuracy trade-off due to its susceptibility to well described 
overestimation artefacts. These could potentially overestimate the reduction of PORC over 
time. 72–78 
The fact that acceleromyography has been used as the exclusive PORC quantification 
method on every study inluded after the year 2005 (cumulatively, 69,2% of the included 
studies) illustrates the potential magnitude of this effect.  
Nonetheless, it should be emphasized that the clinical implications of the conclusions 
relating to qualitative monitoring are not invalidated by the possible aforementioned bias. In 
fact, despite increasing awareness and cumulative PORC incidence reduction over time 
even with qualitative methods, the fact that the latter failed to statistically differentiate itself 
from the absence of monitoring is not obviated. This conclusion bears particular relevance 
amid reports of a still high proportional use of qualitative NMM as well as tendencies of 
overconfidence and overestimation in terms of NMM management.5–7 
The abovementioned acceleromyographic limitations have recently been resurfaced as 
grounds for the enforcement of more strict cut-offs for the definition of PORC. In fact, a post-
hoc analysis of the POPULAR study has put forward a 7.8 percentual point adjusted risk 
reduction in post-operative pulmonary complications associated with the raising of the TOFR 
cut-off for extubation from 0.9 to 0.95.21,86,87 This recognition of the importance of full 
neuromuscular recovery is similarly seen in publications using unity as the recovery cut-
off.11, 34 Due to the paucity of studies using these more restrictive TOFR values, a pooled 
analysis on the light of these raised cut-offs was not possible. Although a concordant 
widening of the difference gap between quantitative and qualitative/absent NMM modalities 
is intuitively expected when raising the TOFR, only the systematized anaesthetic community 
adoption of these cut-offs will allow of a later reiteration of their superiority. 
Finally, the present analysis should be interpreted with the accompanying confidence 
analysis in the NMA. Although the CINeMA analysis didn’t raise overwhelming concerns on 
the likelihood of this meta-analysis’ conclusions to be modified by upcoming trials (geometric 
simplicity, stable heterogeneity, imprecision, indirectness and incoherence), significant 
within- and across-study bias concerns were found relating to the relationship between 
intermediate-duration NMBAs and all NMM modalities. The individual GRADE classification 
reflects similarly an overwhelming dominance of studies with a very low level of evidence. 
These are additional limiting issues that should be considered for the interpretation of the 
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At PACU arrival Acceleromyography 
90 Intermediate VA Qualitative Neostigmine 12 15 NR 
2010 Baykara 
13 




76 Intermediate VA Quantitative Neostigmine 3 11 NR 
At PACU arrival Acceleromyography 




99 Intermediate VA Qualitative Neostigmine NR 51 NR 
Within 5 minutes of 
arrival at the PACU 
Acceleromyography 




28 Intermediate VA None Neostigmine NR 3 NR 
At PACU arrival Acceleromyography 29 Intermediate VA None Neostigmine NR 5 NR 
27 Intermediate VA None Neostigmine NR 3 NR 
2012 Kumar 
39
 PFT, PORC 
50 Intermediate VA None Neostigmine NR 23 NR 
At PACU arrival Acceleromyography 50 Intermediate VA None Neostigmine NR 33 NR 




23 Intermediate VA Quantitative Neostigmine 3 8 NR 
At PACU arrival. Acceleromyography 






















184 Intermediate VA None None 49 51 12 
Within 10 minutes 
of arrival at the 
PACU 
Acceleromyography 




51 Intermediate VA None Neostigmine NR 4 NR 
At PACU arrival Acceleromyography 94 Intermediate VA None Neostigmine NR 13 NR 




64 Intermediate NR Quantitative Sugammadex NR 0 NR 
At PACU arrival Acceleromyography 




150 Intermediate VA Qualitative Neostigmine 9 45 NR 
At PACU arrival Acceleromyography 
149 Intermediate VA Qualitative Neostigmine 25 86 NR 
2015 El-Tahan 43
 
PORC 33 Intermediate VA Quantitative Neostigmine 0 2 NR 
















Quantitative None NR 0 NR 
2016 Yazar 
49 
PORC 60 Intermediate VA Quantitative Sugammadex NR 1 NR 






285 Intermediate NR NR NR NR 58 NR 
At PACU arrival Acceleromyography 
































60 Intermediate TIVA Quantitative Neostigmine 0 2 0 




60 Intermediate TIVA Quantitative Neostigmine 0 4 0 
2016 G-Cardenas 
40 
PORC 228 Intermediate NR Quantitative 
Neostigmine (17)  
Sugammadex (15) 




62 Intermediate VA None Neostigmine NR NR 28 
At PACU arrival Acceleromyography 




47 Intermediate VA Quantitative Neostigmine NR 0 NR 
15 minutes after 
PACU arrival 
Acceleromyography 
43 Intermediate VA Quantitative None NR 0 NR 
2018 Thilen 
32 
PORC 41 Intermediate VA Qualitative Neostigmine 1 22 NR 
At tracheal 
Acceleromyography 




















53 Intermediate VA Quantitative Sugammadex NR 0 NR 








171 NR NR Qualitative Neostigmine NR 112 NR 
At tracheal 
extubation 
Acceleromyography 2 NR NR Qualitative None NR 1 NR 
81 NR NR None Neostigmine NR 51 NR 




36 Intermediate VA None Neostigmine NR 6 NR 
At PACU arrival Acceleromyography 
36 Intermediate VA Quantitative Neostigmine NR 1 NR 
Table 1 - Summary of studies included in the meta-analysis. 
VA - Volatile Anaesthesia; TIVA - Total Intravenous Anaesthesia; NR - Not reported; PACU – Post Anesthesia Care Unit; PORC – Post 
Operative Residual Curarization; PFT – Pulmonary function tests; NMM – Neuromuscular Monitoring 
PORC determination time-point: point in time at which the TOF ratio was measured and used to define the presence or absence of PORC 































Suspected No concerns No concerns No concerns No concerns 





Quantitative vs. Quantitative vs. No NMM 
Patients: Adults patients. 
Setting: Elective surgical procedures under general anaesthesia in operation room setting 
requiring administration of intermediate duration NMBAs. 
Intervention: Quantitative or Qualitative Neuromuscular Monitoring 



















































0.352 0.920 0.383 18 11 20 
Table 3 - Summary of Findings for intermediate NMBAs and PORC defined by a TOF-ratio 
<0.9. 





Legends to figures 
 
Figure 1. - Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
flow diagram 
 
Figure 2. - Main Model with subtracted anaesthesia type, Cut-off 0.9 - Forest plot - Pooled 
postoperative residual curarization PORC proportions.  
Study arm label structure (left): Author, publication year, NMM subtype, NMBA duration 
category. Individual and pooled PORC rates and respective 95% Confidence Intervals 
presented on the right hand side of the plot. 
NMM - Neuromuscular monitoring subtype; none - no NMM; pns - qualitative NMM; tft - 
Quantitative monitoring; imed=intermediate - intermediate duration NMBAs; long - Long 
duration NMBAs. 
For intermediate duration NMBAs, the use of quantitative neuromuscular monitoring is 
associated with lower PORC rates when compared to both no monitoring and qualitative 
monitoring, as exemplified by the absence of overlap of the respective confidence intervals. 
 
Figure 3. - Trend Model, Cut-off 0.9 - Isolated proportion plotting - Publication year vs 
Neuromuscular monitoring type (monitor). 
There is a global reduction in the incidence of PORC with time, independently of the subtype 
of Neuromuscular monitoring. Although the chronological decrease is most evident when no 
monitoring is used, the PORC are consistently higher when compared to quantitative 
monitoring. 
 
Figure 4. – Funnel plotting per statistical model and TOF-ratio cut-off. x axis: residual value, 
y axis: standard error; A - Main Model with subtracted anesthesia type, Cut-off 0.9; B– 
Antagonist Model, Cut-off 0.7; C - Antagonist Model, Cut-off 0.9; D - Main Model, Cut-off 0.7; 
E - Main Model, Cut-off 0.9; F - Trend Model, Cut-off 0.7; G - Trend Model, Cut-off 0.9. 
There is no serious indication of any systematic heterogeneity bias. For the antagonist 
model with a cut-off of 0.7, one study clearly shows a proportion that is different from what 
would be expected based on the available information in the model.23 
 
 
